#Axsome
LightNews LightNews
blueresearch.bsky.social
Axsome Therapeutics price target lowered by $26 at Morgan Stanley
Reported Friday, Nov 13 - 6:26am EST (TheFly subscription required to read more.)
thefly.com
November 13, 2026 at 11:30 AM
merlintrader.bsky.social
$AXSM Axsome Therapeutics: Q3 net product revenue up 52% to $259.7M (Q3 2026)
Hub: https://www.merlintrader.com/axsome-therapeutics-axsm-stock-hub-2026/?utm_source=bluesky&utm_medium=social&utm_campaign=flyer-q3-2026&utm_content=axsm

Not investment advice.
image
November 10, 2026 at 6:05 PM
merlintrader.bsky.social
$AXSM: investor conference presentation Nov 9 confirmed.
Hub: https://www.merlintrader.com/axsome-therapeutics-axsm-stock-hub-2026/
Newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13
image
November 9, 2026 at 1:30 PM
gta-terminal.bsky.social
Options money in #$AXSM: $1.3M calls vs $684K puts, $2.0M in all (65% calls).
Off-exchange (dark pool) shares, % of volume: Nov 11 476,720 (44.4%).
Dark pool trading Nov 11 hit 1.0x a normal day (5-day trend: fading).

Full story at the link.
#optionsflow #stocks #optionstrading #stockmarket
Axsome (AXSM) Technical Levels: Options Flow Mixed Between $145 and $170
AXSM at $149.24: support $145.42, resistance $169.96; the chart, options flow and dark pools are mixed.
globaltradersacademy.com
November 12, 2026 at 11:05 AM
merlintrader.bsky.social
$AXSM: Axsome's Q3 net product revenue rose 52% to $259.7M; AUVELITY sales grew 53% to $207.6M and the net loss narrowed to $12.9M. Not investment advice.

https://www.merlintrader.com/axsome-therapeutics-axsm-stock-hub-2026/
image
November 8, 2026 at 9:55 AM
merlintrader.bsky.social
#$AXSM — Axsome: Q3 revenue $259.7M, up 52% y/y; AUVELITY sales $207.6M (+53%).
GAAP net loss narrowed to $12.9M; cash $313.9M at Sep 30.

AXSM Stock Hub: Axsome Therapeutics News, AUVELITY and AXS-12
www.merlintrader.com/axsome-thera...
November 4, 2026 at 2:24 PM
blueresearch.bsky.social
Axsome Therapeutics price target lowered by $12 at Mizuho
Reported Wednesday, Nov 4 - 7:22am EST (TheFly subscription required to read more.)
thefly.com
November 4, 2026 at 12:31 PM
merlintrader.bsky.social
Axsome #$AXSM lined up a busy November investor conference schedule.

Shares closed at $136.01 Mon: below SMA50, below SMA200, RSI 20 (oversold).

Hub: www.merlintrader.com/axsome-thera...

Not investment advice.
AXSM Stock: Axsome Therapeutics News, AUVELITY & AXS-12
Axsome Therapeutics stock news and analysis: revenue from three marketed medicines, AXS-12 review, ENGAGE data, cash use, debt and the key risks for AXSM.
www.merlintrader.com
November 3, 2026 at 4:09 PM
blueresearch.bsky.social
Axsome Therapeutics price target lowered by $22 at Deutsche Bank
Reported Tuesday, Nov 3 - 9:23am EST (TheFly subscription required to read more.)
thefly.com
November 3, 2026 at 2:31 PM
blueresearch.bsky.social
Axsome Therapeutics price target lowered by $25 at Guggenheim
Reported Tuesday, Nov 3 - 6:52am EST (TheFly subscription required to read more.)
thefly.com
November 3, 2026 at 12:01 PM
blueresearch.bsky.social
Axsome Therapeutics price target raised by $2 at Morgan Stanley
Reported Tuesday, Nov 3 - 7:49am EST (TheFly subscription required to read more.)
thefly.com
November 3, 2026 at 12:50 PM
blueresearch.bsky.social
BofA trims Axsome Therapeutics price target, says selloff overdone
Reported Tuesday, Nov 3 - 6:33am EST (TheFly subscription required to read more.)
thefly.com
November 3, 2026 at 11:40 AM
blueresearch.bsky.social
Axsome Therapeutics price target lowered by $26 at Baird
Reported Tuesday, Nov 3 - 6:24am EST (TheFly subscription required to read more.)
thefly.com
November 3, 2026 at 11:30 AM
blueresearch.bsky.social
Axsome Therapeutics price target lowered by $17 at UBS
Reported Monday, Nov 2 - 8:59pm EST (TheFly subscription required to read more.)
thefly.com
November 3, 2026 at 2:01 AM
stocktitan.net
#AXSM Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

https://www.stocktitan.net/news/AXSM/axsome-therapeutics-reports-third-quarter-2026-financial-results-and-9cjpq97qtfvy.html?utm_source=stocktitan-bluesky&utm_medium=social
www.stocktitan.net
November 2, 2026 at 12:00 PM
blueresearch.bsky.social
Axsome Therapeutics price target lowered by $22 at RBC Capital
Reported Monday, Nov 2 - 9:07pm EST (TheFly subscription required to read more.)
thefly.com
November 3, 2026 at 2:11 AM
blueresearch.bsky.social
Axsome Therapeutics falls -10.9%
Reported Monday, Nov 2 - 10:00am EST (TheFly subscription required to read more.)
thefly.com
November 2, 2026 at 3:03 PM
blueresearch.bsky.social
Axsome shares 'significantly undervalued,' says TD Cowen
Reported Monday, Nov 2 - 2:44pm EST (TheFly subscription required to read more.)
thefly.com
November 2, 2026 at 7:51 PM
blueresearch.bsky.social
Axsome Therapeutics price target lowered by $75 at Jefferies
Reported Monday, Nov 2 - 2:01pm EST (TheFly subscription required to read more.)
thefly.com
November 2, 2026 at 7:11 PM
blueresearch.bsky.social
Axsome Therapeutics price target lowered by $3 at Piper Sandler
Reported Monday, Nov 2 - 12:14pm EST (TheFly subscription required to read more.)
thefly.com
November 2, 2026 at 5:21 PM
blueresearch.bsky.social
Axsome Therapeutics reports Q3 EPS (25c), consensus (56c)
Reported Monday, Nov 2 - 10:23am EST (TheFly subscription required to read more.)
thefly.com
November 2, 2026 at 3:32 PM
nexusfinance.bsky.social
📅 EQB will report its Q4 and fiscal 2026 financial results after market close on December 2, 2026.
📊 Axsome Therapeutics published its Q3 2026 earnings presentation and results slide deck.
November 2, 2026 at 10:18 PM
fundspec.bsky.social
Axsome Therapeutics $AXSM reported Q3 2026 EPS of -$0.25, beating the -$0.64 estimate by 60.9%. Revenue of $259.7M beat the $248.6M estimate by 4.4%.

https://fundspec.ai/s/AXSM/earnings
Get a push the moment an analyst moves a price target.
November 2, 2026 at 12:06 PM
quant-hub.bsky.social
🚨 $AXSM
On November 2, 2026, Axsome Therapeutics, Inc. issued a press release announcing its financial results for the three months ended September 30, 2026, and provided an update on the Company’s operations.
SEC Filing: AXSM
Click to view the official SEC document.
www.sec.gov
November 2, 2026 at 12:06 PM
merlintrader.bsky.social
#$AXSM weekly close $144.43 (-0.4% w/w), below SMA50 $184.76 / below SMA200 $199.33, RSI 24.3. Support $131.26, resistance $179.70.

New hub updated: www.merlintrader.com/axsome-thera...
AXSM Stock: Axsome Therapeutics News, AUVELITY & AXS-12
Axsome Therapeutics stock news: $218.4M Q2 revenue, $319.9M June cash, November 2results and a May 1, 2027 AXS-12 target action date.
www.merlintrader.com
October 31, 2026 at 7:27 AM